Pacritinib May Benefit Patients with Myelofibrosis and Thrombocytopenia

A recent phase III study revealed a benefit with pacritinib for patients with myelofibrosis and thrombocytopenia who have experienced treatment failure with previous therapies.

Source: CancerNetwork - March 21, 2018 Category: Cancer & Oncology Authors: John Schieszer Tags: Hematologic Malignancies Myeloproliferative Neoplasms News Source Type: news